Study of Blood Samples in Patients With Breast Cancer
Primary Purpose
Breast Cancer
Status
Unknown status
Phase
Locations
France
Study Type
Observational
Intervention
laboratory biomarker analysis
Sponsored by
About this trial
This is an observational trial for Breast Cancer focused on measuring recurrent breast cancer, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IV breast cancer
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed breast carcinoma
- Received first-line chemotherapy (in neoadjuvant or metastatic setting) comprising anthracyclines and/or taxanes, including for a second primary cancer
- Patient agrees to conservative surgery
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- No contraindication for chemotherapy comprising anthracyclines and/or taxanes
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior adjuvant therapy
Sites / Locations
- Centre Oscar LambretRecruiting
Outcomes
Primary Outcome Measures
Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00959556
Brief Title
Study of Blood Samples in Patients With Breast Cancer
Official Title
Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting
Study Type
Observational
2. Study Status
Record Verification Date
August 2009
Overall Recruitment Status
Unknown status
Study Start Date
November 2007 (undefined)
Primary Completion Date
December 2011 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Centre Oscar Lambret
4. Oversight
5. Study Description
Brief Summary
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to chemotherapy.
PURPOSE: This clinical trial is studying blood samples in patients with breast cancer.
Detailed Description
OBJECTIVES:
Identify constitutional gene variants associated with a change in response.
OUTLINE: Blood samples are collected periodically for analysis of genetic factors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
recurrent breast cancer, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IV breast cancer
7. Study Design
Enrollment
900 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Primary Outcome Measure Information:
Title
Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed breast carcinoma
Received first-line chemotherapy (in neoadjuvant or metastatic setting) comprising anthracyclines and/or taxanes, including for a second primary cancer
Patient agrees to conservative surgery
Hormone receptor status not specified
PATIENT CHARACTERISTICS:
Menopausal status not specified
No contraindication for chemotherapy comprising anthracyclines and/or taxanes
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
No prior adjuvant therapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacques Bonneterre, MD, PhD
Organizational Affiliation
Centre Oscar Lambret
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Oscar Lambret
City
Lille
ZIP/Postal Code
59020
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jacques Bonneterre, MD, PhD
Phone
33-3-20-29-5959
Email
j.bonneterre@o-lambret.fr
12. IPD Sharing Statement
Learn more about this trial
Study of Blood Samples in Patients With Breast Cancer
We'll reach out to this number within 24 hrs